心肌显像剂99TcmN(NOEt)2动物药理实验和再分布特性

目的对心肌显像剂99Tcm-氮-二(N-乙基-N-乙氧基二硫代氨基甲酸盐)[N(NOEt)2]进行临床前药理实验和再分布特性研究.方法制备的99TcmN(NOEt)2放化纯度>95%,对5只实验犬进行了血药动力学、体内生物分布和显像、99TcmN(NOEt)2和201Tl缺血心肌再分布显像对比和毒性的研究.结果 99TcmN(NOEt)2的放化纯度平均为(98.41±0.46)%,血清除T(α)1/2=(2.8±0.1) min,T(β)1/2=(142.7±32.7) min,总清除速率Cl=(292.3±117.1) mL/h.显像示99TcmN(NOEt)2能被心肌较快地摄取,肺中摄取清除快速,肝摄取较高.在10、30、60、90、120 min时,心肌摄取为(4.27±0.21)、(5.3±1.48)、(5.3±0.66)、(4.0±0.53)和(3.67±0.35)%ID;心/肺和心/肝比值分别是1.24±0.31、2.03±0.45、2.33±0.31、2.23±0.5、2.07±0.49和0.94±0.08、0.78±0.15、0.56±0.22、0.53±0.22、0.38±0.15.在30和60 min时心肌影像最为清晰.99TcmN(NOEt)2在犬缺血心肌中有再分布特征,并与201Tl的再分布显像自身对照结果一致.结论 99TcmN(NOEt)2是很有价值的心肌灌注显像剂,并有与201Tl一样的再分布特征.     

有关核心脏病学中的若干问题探讨

介绍了目前核心脏病学中存在的几个问题,重点讨论了心肌显像剂99mTc-MIBI、99mTctetrofosmin、99mTc-teboroxime和核心脏病学在冠心病预后的估价、心肌再灌注、充血性心力衰竭中的临床应用情况。     

新型心肌灌注显像剂~(99)Tc~mN-MIBI的药盒研制及质量控制

目的　建立心肌灌注显像剂99TcmN 甲氧基异丁基异腈 (MIBI)的药盒法制备及其质量控制方法。方法　由条件实验确定药盒中各组分的最佳含量。参照《中国药典》(1995年版 )方法进行澄清度、pH值、无菌以及急性毒性检查。将药盒置于不同环境下存放不同时间 ,通过外观、主药含量及配合物标记率的变化来检查药盒的稳定性。结果　药盒的澄清度、pH值、无菌以及急性毒性检查合格 ,稳定性好。药盒法制备的配合物标记率大于 95 %。结论　药盒法制备99TcmN MIBI配合物简便易行 ,符合临床试用要求。     

99Tcm标记异腈类配合物的研究进展

99Tcm标记的异腈类配合物是目前国内外应用最广泛的心肌灌注显像剂,在肿瘤的诊断方面也有重要应用.本文简要介绍了异腈配体合成及标记化合物的制备方法,并对99Tcm标记异腈类配合物的发展、分类及应用进展作了归纳总结.     

五种99mTc标记的心肌灌注显像剂

综述了临床广泛使用以及正在开发和评估的五种99mTc标记的心肌灌注显像剂的制备与质量控制、生物学行为及临床用途。     

心脏显像剂的现状及进展

对心脏显像剂在心血池显像,心肌灌注显像、心肌代谢显像中的应用现状和进展作了综述,并介绍了分子核心脏病学显像中的展望。认为深入开展心脏显像剂的开发和利用对核心脏病学的研究具有重要意义。     

国产锝[99Tcm]替曲膦注射液临床验证研究

目的 研究锝[99Tcm]替曲膦注射液一步法新药盒用于心肌灌注显像的效果及安全性.方法 采用随机、双盲、平行、对照设计.以习用的心肌灌注显像剂99Tcm-甲氧基异丁基异腈(MIBI)为锝[99Tcm]替曲膦的对照药物.确定入选者符合标准并签署知情同意书后,进行双嘧达莫(潘生丁)负荷和静息心肌显像.观察心肌显像前后的生命体征和有无不良反应.由2位核医学科医师双盲判读心肌显像图并对图像质量作出评价.结果 100例病例人组锝[99Tcm]替曲膦心肌显像(试验)组,108例入组99Tcm-MIBI对照组.所有病例均未观察到使用心肌显像药物引起的不良反应.试验组100例均获得合格的心肌影像并足以提供诊断依据,心肌影像质量良好.与对照组相比,心肌影像质量没有明显差异.结论 锝[99Tcm]替曲膦注射液标记简便,制剂稳定,心肌影像图像质量优良,且使用安全.     

胶质瘤显像剂的研究与应用进展

核医学显像在胶质瘤的诊断、分级及预后等方面有重要的临床价值,随着核医学的发展,用于胶质瘤的显像剂也越来越多样化,目前研究应用较多的SPECT显像剂有201Tl、99Tcm-MIBI、123I-碘代甲基酪氨酸以及新型受体类显像剂131I-蝎氯毒素等,PET显像剂主要有葡萄糖代谢显像剂、氨基酸代谢显像剂、胆碱代谢显像剂、核...     

^99Tc^m标记异腈类配合物的研究进展

^99Tc^m标记的异腈类配合物是目前国内外应用最广泛的心肌灌注显像剂，在肿瘤的诊断方面也有重要应用。本简要介绍了异腈配体合成及标记化合物的制备方法．并对^99Tc^m标记异腈类配合物的发展、分类及应用进展作了归纳总结。     

心肌灌注显像剂:99Tcm-N-NOET

99Tcm-N-NOET{双[N-乙氧,N-乙基(二硫代氨基甲酸脂)氮化锝](V)}是一种锝标记中性亲脂性心肌灌注显像剂,具有心肌首过摄取率高、心肌滞留时间长之优点.其心肌摄取部位在细胞膜,且摄取不依赖于能量.L型钙通道阻滞剂能影响其心肌摄取.99Tcm-N-NOET不仅具有201Tl类似的心肌再分布,而且其心肌灌注显像在诊断冠状动脉疾病的敏感性和特异性方面与201Tl类似.     

Knee injury and Osteoarthritis Outcome Score (KOOS) - validation of a Swedish version

The Knee injury and Osteoarthritis Outcome Score (KOOS) is a self-administered instrument measuring outcome after knee injury at impairment, disability, and handicap level in five subscales. Reliability, validity, and responsiveness of a Swedish version was assessed in 142 patients who underwent arthroscopy because of injury to the menisci, anterior cruciate ligament, or cartilage of the knee. The clinimetric properties were found to be good and comparable to the American version of the KOOS. Comparison to the Short Form-36 and the Lysholm knee scoring scale revealed expected correlations and construct validity. Item by item, symptoms and functional limitations were compared between diagnostic groups. High responsiveness was found three months after arthroscopic partial meniscectomy for all subscales but Activities of Daily Living.     

Endovascular management of carotid-cavernous fistulas

Objective To investigate endovascular treatment of traumatic direct carotid-cavernous fistulas （CCF） and their complications such as pseudoaneurysms. Methods： Over a five-year period, 22 patients with traumatic direct CCFs were treated endovascularly in our institution. Thirteen patients were treated once with the result of CCF occluded, 8 twice and 1 three times. Treatment modalities included balloon occlusion of the CCF, sacrifice of the ipsilateral internal carotid artery with detachable balloon, coll embolization of the cavernous sinus and secondary pseudoaneurysms, and covered-stem management of the pseudoaneurysms. Results All the direct CCFs were successfully managed endovascularly. Four patients developed a pseudoaneurysm after the occlusion of the CCF with an incidence of pseudoaneurysm formation of 18.2% （4/22）. A total number of 8 patients experienced permanent occlusion of the ICA with a rate of ICA occlusion reaching 36.4% （8/22）. Followed up through telephone consultation from 6 months to 5 years, all did well with no recurrence of CCF symptoms and signs. Conclusion Traumatic direct CCFs can be successfully managed with endovascular means. The pseudoaneurysms secondary to the occlusion of the CCFs can be occluded with stent-assisted coiling and implantation of covered stents.     

The acutely limping child

Acute limping may be the result of multiple pathologies in children. The differential diagnosis varies based on the age of the child. Irrespective of age, the initial imaging work-up includes AP and frog leg radiographs of the pelvis and ultrasound; MRI may sometimes be helpful. In children less than 3 years, infections and trauma are most frequent. MRI is the imaging modality of choice when osteomyelitis is clinically suspected. Between the ages of 3 and 10 years, transient synovitis of the hip and Legg-Calvé-Perthes disease are main considerations but infection, inflammation and focal bony lesions are also considered. In children over 10 years, slipped capital femoral epiphysis also is considered.     

Do Balance Board Training Programs Reduce the Risk of Ankle Sprains in Athletes?

Introduction Ankle sprains are the most common musculo-skeletal injury that occurs in athletes,particularly in sports that require jumping and landing on one foot such as soccer,and basketball(1-4).These injuries often result in significant time loss from participation,long-term disability,and have a major impact on health care costs and resources(5-8).     

High Intensity Interval Training:New Insights

KEY POINTS ·High-intensity interval training(HIT)is characterized by repeated sessions of relatively brief，intermittent exercise.often performed with an“a11 out”effort or at an intensity close to that which elicits peak oxygen uptake(i.e.，≥90%of VO2 peak).     

Developmental validation of the PowerPlex(®) ESI 16 and PowerPlex(®) ESI 17 Systems: STR multiplexes for the new European standard

In response to the ENFSI and EDNAP groups’ call for new STR multiplexes for Europe, Promega^® developed a suite of four new DNA profiling kits. This paper describes the developmental validation study performed on the PowerPlex^® ESI 16 (European Standard Investigator 16) and the PowerPlex^® ESI 17 Systems. The PowerPlex^® ESI 16 System combines the 11 loci compatible with the UK National DNA Database^®, contained within the AmpFlSTR^® SGM Plus^® PCR Amplification Kit, with five additional loci: D2S441, D10S1248, D22S1045, D1S1656 and D12S391. The multiplex was designed to reduce the amplicon size of the loci found in the AmpFlSTR^® SGM Plus^® kit. This design facilitates increased robustness and amplification success for the loci used in the national DNA databases created in many countries, when analyzing degraded DNA samples. The PowerPlex^® ESI 17 System amplifies the same loci as the PowerPlex^® ESI 16 System, but with the addition of a primer pair for the SE33 locus. Tests were designed to address the developmental validation guidelines issued by the Scientific Working Group on DNA Analysis Methods (SWGDAM), and those of the DNA Advisory Board (DAB). Samples processed include DNA mixtures, PCR reactions spiked with inhibitors, a sensitivity series, and 306 United Kingdom donor samples to determine concordance with data generated with the AmpFlSTR^® SGM Plus^® kit. Allele frequencies from 242 white Caucasian samples collected in the United Kingdom are also presented. The PowerPlex^® ESI 16 and ESI 17 Systems are robust and sensitive tools, suitable for the analysis of forensic DNA samples. Full profiles were routinely observed with 62.5 pg of a fully heterozygous single source DNA template. This high level of sensitivity was found to impact on mixture analyses, where 54–86% of unique minor contributor alleles were routinely observed in a 1:19 mixture ratio. Improved sensitivity combined with the robustness afforded by smaller amplicons has substantially improved the quantity of data obtained from degraded samples, and the improved chemistry confers exceptional tolerance to high levels of laboratory prepared inhibitors.